AyoHealth is seeking ₦150–300M in seed capital to become Nigeria's premier diagnostic distribution and health intelligence platform — serving pharmacists, clinics, and patients across Lagos and Abuja.
Nigeria is the world's largest malaria burden country (27% of global cases), contributes 28.3% of all global maternal deaths, and has over 11.4 million diagnosed diabetics — yet rapid diagnostic test availability in private pharmacies sits below 22%. No single platform connects the pharmacists, clinics, and labs that serve Nigeria's 220 million people into a coordinated diagnostic intelligence network.
AyoHealth closes this gap through three interlocked business layers: a licensed diagnostic distribution operation (importing and delivering NAFDAC-cleared kits to 800+ outlets by Month 6), a proprietary bundled kit product line (four SKUs designed for clinical use cases), and AyoIntel — Nigeria's first diagnostic intelligence platform, delivering WhatsApp AI tools to pharmacists, AI symptom triage to patients, real-time inventory tracking, and disease surveillance dashboards.
The business generates revenue from five streams: distribution margins (45–60%), bundled kit premiums (55–65%), SaaS platform subscriptions (~85%), data intelligence reports, and health facility registry listings — with a blended gross margin target of 52–58% and an expected break-even at Month 8–10.
Supply failure: Over 90% of Nigeria's rapid diagnostic kits are imported, with no coordinated private-sector distribution network. With USAID procurement support withdrawn in 2025, the supply chain is actively fragile. Only 22% of private pharmacies stock malaria RDTs. Bundled diagnostic kits designed for specific clinical presentations do not exist in the market.
Intelligence failure: Nigeria has no mechanism for aggregating real-time diagnostic data from its private pharmacy and clinic network. Disease outbreak signals are invisible until they reach public hospitals. Pharmacists restock reactively, after stockouts. There is no equivalent of a diagnostic intelligence layer anywhere in Nigeria's private health sector.
Behaviour failure: Presumptive diagnosis — treating fever as malaria without testing — remains dominant. Half of households have never heard of malaria RDTs. Patients in Nigeria's two largest cities have no trusted, affordable way to triage symptoms outside business hours without visiting expensive private emergency rooms.
The three layers are mutually reinforcing: distribution generates clients for the platform; the platform generates data that powers intelligence reports; intelligence reports attract institutional clients that generate bulk distribution orders. Each layer increases the switching cost of the other two.
The withdrawal of US funding for West African diagnostic procurement in 2025 created an immediate supply vacuum. Codix Bio — Nigeria's WHO-licensed kit manufacturer (147M kits/year) — is actively seeking commercial distributors. First-movers get preferred pricing.
President Tinubu's 2024 Executive Order: zero tariffs and VAT on RDT imports for 2 years. This dramatically reduces COGS for distributors. The window closes; acting now locks in the cost structure advantage.
Nigeria's Pharmacy Council launched the Electronic Pharmacy Regulation Platform in April 2026 — creating a legal framework for digital diagnostic distribution. AyoHealth can register as a founding platform participant.
| Scenario | Active Accounts (M12) | Month 12 MRR | Year 1 Revenue | Break-Even |
|---|---|---|---|---|
| Worst Case | 200 | ₦2.2M | ₦14.6M | Month 14–16 |
| Expected Case | 600 | ₦7.5M | ₦51.3M | Month 8–10 |
| Best Case | 1,200 | ₦20M | ₦109.8M | Month 5–6 |
Every kit dispensed generates diagnostic and inventory data that competitors cannot replicate without matching the distribution network. AyoIntel becomes more valuable with each additional pharmacy that joins.
As more pharmacies share inventory data, the disease-tracking dashboard becomes more accurate — attracting labs, clinics, and eventually government health agencies as data buyers.
Pharmacists trained on the AyoPharm WhatsApp workflow will not switch to email-based or app-based alternatives. WhatsApp is the primary business communication tool for Nigerian SMEs.
Proprietary assembly of multi-test kits creates margin and brand differentiation that no pure distributor can replicate. Kit designs are optimised for each clinical presentation, not just component convenience.
Operating as a licensed distributor under the new PCN e-Pharmacy framework (April 2026) positions AyoHealth ahead of any new entrant that has not yet registered. NAFDAC clearances take 6+ months.
Lagos-based; thesis includes health tech and infrastructure. Prior investments in Nigerian health and logistics.
Africa-focused; deep health systems portfolio. Alignment with diagnostics access and bottom-of-pyramid health markets.
Pan-African tech; data and platform businesses. AyoData intelligence revenue aligns with their data-asset thesis.
Lagos Angel Network; individual health sector angels. For ₦15–50M bridge round prior to formal seed close.
AyoHealth is not a diagnostics company that built a chatbot. It is a data and intelligence platform that uses diagnostic distribution as its go-to-market flywheel. The business earns while it builds the moat.